Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Seaside Therapeutics awarded Autism Speaks grant

Sep. 21, 2006

Schering-Plough presents new lead BACE1 inhibitor

Sep. 21, 2006

Wyeth presents novel Kv channel disinactivator, with efficacy in a seizure model

Sep. 21, 2006

Ralfinamide blocks chronic pain behavior and underlying neural ectopic activity

Sep. 21, 2006

DHEA beneficial for long-term morphine use

Sep. 21, 2006

Selective norepinephrine reuptake inhibitors developed by Wyeth

Sep. 20, 2006

Opexa Therapeutics provides update on preclinical and clinical progress

Sep. 20, 2006

Pfizer and Trans Tech Pharma to develop RAGE products for Alzheimer's disease

Sep. 20, 2006

Recent patents divulge novel analgesic agents

Sep. 20, 2006

Analgesic properties of the anticancer agent BIM-46187

Sep. 20, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...